Search company, investor...
Biofourmis company logo

Biofourmis

biofourmis.com

Founded Year

2015

Stage

Series D - II | Alive

Total Raised

$461.85M

Last Raised

$20M | 8 mos ago

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+20 points in the past 30 days

About Biofourmis

Biofourmis discovers, develops, and delivers clinically-validated, software-based therapeutics. Biofourmis has built Biovitals, a personalized, AI-powered health analytics platform that predicts clinical exacerbation in advance of a critical event, which is the backbone of its digital therapeutics product pipeline across multiple therapeutic areas, including heart failure, oncology, acute coronary syndrome, COPD, and chronic pain. It serves clients operating in the healthcare sector. The company was founded in 2015 and is based in Boston, Massachusetts.

Headquarters Location

33 Arch Street Floor 17

Boston, Massachusetts, 02110,

United States

(617) 334-5441

ESPs containing Biofourmis

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTH ➡MARKET STRENGTH ➡LEADERHIGHFLIEROUTPERFORMERCHALLENGER
Healthcare / Healthcare Providers Tech

Companies in this market aim to improve outcomes and reduce the cost of care for the world’s estimated 18.1M cancer patients (as of 2020, per WCRF International). This includes companies that proactively diagnose cancer through the use of AI and those developing more effective treatments and monitoring apps for cancer patients.

Biofourmis named as Leader among 12 other companies, including Tempus, CureApp, and Jasper Health.

Compete with Biofourmis?

Ensure that your company and products are accurately represented on our platform.

Biofourmis's Products & Differentiators

    Biovitals RPM

    Remote patient monitoring platform

Expert Collections containing Biofourmis

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Biofourmis is included in 15 Expert Collections, including Digital Health.

D

Digital Health

13,903 items

Companies developing and enabling evidence-based, software-driven therapeutic interventions to prevent, manage, or treat a medical disorder or disease. (*Scope follows the Digital Therapeutics Alliance definition)

U

Unicorns- Billion Dollar Startups

1,207 items

A

Artificial Intelligence

10,393 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

D

Digital Health 150

300 items

2019's cohort of the most promising digital health startups transforming the healthcare industry

V

Value-Based Care & Population Health

1,066 items

The VBC & Population Health collection includes companies that enable and deliver care models that address the health needs for defining populations along the continuum of care, including in the community setting, through participation, engagement, and targeted interventions.

M

Medical Devices

12,358 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

Latest Biofourmis News

A closer look at the 8 unicorns of Southeast Asia minted last year

Mar 27, 2023

Tech Collective The total number of tech unicorns Southeast Asia is home to increased marginally last year with eight privately-held companies receiving enough funding to cross over the USD 1 billion valuations, achieving the “unicorn” status. The eight newly-minted unicorns represented a significant drop from the twenty-three record of unicorns minted in 2021. According to The Straits Times, 2021’s unicorns of Southeast Asia came about in large numbers due to several factors ; growing smartphone usage, a young demographic, increased private equity funding, and an expanding middle class. For 2022, the massive drop-off was because of the global economic slowdown, which has led to a reduction in investment. Here is how Vietnam’s tech growth will help mint more unicorn startups in Southeast Asia DealStreetAsia reported that Southeast Asian companies only raised USD 2.88 billion in the fourth quarter (Q4)of 2022, a two-year low. Moreover, there was a 32% drop in private funding compared to 2021’s record figures, going from USD 23.2 billion down to USD 15.8 billion. Thus, only eight companies achieved the unicorn tag, with Singapore and Indonesia getting the most unicorns (three each). Thailand and the Philippines wrapped it up with the remaining two unicorns. Unicorns minted in 2022 According to DealStreetAsia, Singapore has the most unicorns in the Association of Southeast Asian Nations (ASEAN) at twenty-five. Indonesia is next with sixteen, followed by Vietnam with four, Thailand with three, and both the Philippines and Malaysia with two. Singapore’s new unicorns raised the most money in 2022 at USD 9.79 billion, followed by Indonesia at USD 3.77 billion. Together, they accounted for 86% of the total funding of USD 15.8 billion. Deal volume was 554 in Singapore, 259 in Indonesia, 81 in Vietnam, 68 in Malaysia, 58 in the Philippines, and 38 in Thailand. The financial technology (fintech) sector accounted for the majority of the funding, with five of the eight unicorns being fintech companies. Akulaku Indonesia’s fintech company Akulaku received USD 300 million investment from Thailand-based Siam Commercial Bank (SCB) Group in a Series E + Venture Round. Akulaku provides digital banking, wealth management, and other financial services. Insider Singapore’s marketing technology (martech) company, the Insider, received USD 121 million from the Qatar Investment Authority in a Series B funding round. Other investors included Sequoia Capital, Wamda Capital, 212, Esas Private Equity, Riverwood Capital, and Endeavor Catalyst. Insider is a platform for cross-channel and individualised customer experiences. Voyager Innovations Philippine-based Voyager Innovations, also a fintech company, received USD 210 million from SIG Venture Capital in an unspecified round. Other investors included Singapore-based EDBI, First Pacific Company Ltd, Tencent, KKR, the International Finance Corporation, and other funds. Voyager Innovations develops technology for emerging markets to provide digital and financial solutions. Biofourmis Health technology (healthtech) company Biofourmis from Singapore received USD 300 million in a Series D round. Its investors included CVS Health, General Atlantic, OpenSpace Ventures, and EDBI. Biofourmis is a digital therapeutics company that uses artificial intelligence and provides remote health monitoring solutions. Coda Payments Another Singapore-based company, Coda Payments—which operates in the fintech sector—raised the highest number of the companies on the list, getting USD 690 million in a Series C round. It got funding from Singapore’s sovereign wealth fund GIC, Smash Ventures, and Insight Partners. GIC’s investment gave it a minority stake in the company. Coda Payments collects payments for digital content globally, like video on demand (VOD), live and music streaming, online and mobile games, and more. DANA Wallet Indonesia’s fintech company DANA Wallet raised USD 200 million in a Corporate round from the Sinar Mas Group to become a unicorn. DANA Wallet is a digital payment processing solution. LINE MAN Wongnai Thailand-based LINE MAN Wongnai, a restaurant technology-based company, raised USD 285 million in a Series B round. Investors include GIC, BRV Capital Management, and LINE Plus Corporation. LINE MAN Wongnai is an eCommerce platform for services seeking to empower Thai locals and businesses. Kredivo Finally, Indonesia-based fintech company Kredivo, known under the name Fin Accel, received USD 140 million in a Series D round from Naver Financial to become a unicorn. Other investors included Mirae Asset, GMO Global Payment Fund, Cathay Innovation, Square Peg, Openspace Ventures, Jungle Ventures, and Endeavor Catalyst. Kredivo is a buy now, pay later (BNPL) service. Despite the low number in 2022, the tech unicorns Southeast Asia minted provide great value to their communities. Other sectors were not represented but may emerge in the coming years as countries open up after the pandemic. For example, the travel and hospitality sectors may very well provide a future unicorn. Once the global economic challenges decrease, local and foreign investors will start providing more financial backing to create the next best unicorns of Southeast Asia. Governments and other stakeholders must provide adequate startup support to make it a reality. Share this:

Biofourmis Frequently Asked Questions (FAQ)

  • When was Biofourmis founded?

    Biofourmis was founded in 2015.

  • Where is Biofourmis's headquarters?

    Biofourmis's headquarters is located at 33 Arch Street, Boston.

  • What is Biofourmis's latest funding round?

    Biofourmis's latest funding round is Series D - II.

  • How much did Biofourmis raise?

    Biofourmis raised a total of $461.85M.

  • Who are the investors of Biofourmis?

    Investors of Biofourmis include Intel Capital, General Atlantic, CVS Health, OpenSpace Ventures, MassMutual Ventures and 12 more.

  • Who are Biofourmis's competitors?

    Competitors of Biofourmis include Byteflies, Acorai, MayaMD, Healios, MyelinH and 16 more.

  • What products does Biofourmis offer?

    Biofourmis's products include Biovitals RPM and 3 more.

Compare Biofourmis to Competitors

Koneksa Logo
Koneksa

Koneksa is a healthcare technology company developing digital biomarkers to accelerate clinical research and guide decision-making in drug development and market strategy. Its evidence-based biomarker solutions enable efficient clinical trial designs to help therapies reach patients faster. Koneksa specializes in treatment effect detection in clinical research and aims to improve patient outcomes. The company was founded in 2015 and is based in New York, New York.

VitalConnect Logo
VitalConnect

VitalConnect is specializes in wearable biosensor technology for wireless patient monitoring in both hospital and remote patient populations. It leverages extensive expertise in biomedical engineering, data analytics, chip design, and mobile and cloud software to create technology that supports decision-making paradigms that achieve better health and economic outcomes. VitalConnect’s products are designed for use in a broad range of inpatient and outpatient settings, such as hospital monitoring, post-discharge care, cardiac monitoring, and pharmaceutical solutions. VitalConnect’s advanced yet easy-to-use platform aims to deliver better healthcare at lower costs while providing more convenience for the patients and healthcare providers. The company was formerly known as Vigilo Networks. It was founded in 2011 and is based in San Jose, California.

Health Recovery Solutions Logo
Health Recovery Solutions

Health Recovery Solutions helps hospitals, physicians, and patients manage chronic conditions and reduce hospital readmissions by employing a research based platform (PatientConnect) that constructively guides patients' behaviors. The recovery data is used in conjunction with EMR integration, web monitoring portal, and smartphone applications (ClinicianConnect, and CaregiverConnect) to effectively address patients' concerns and use of its products, as well as reinforce healthy lifestyles post hospitalization. It was founded in 2012 and is based in Hoboken, New Jersey.

D
Donisi Health

Donisi Health develops a clinically validated, contact-free device designed for both cardiac and respiratory assessment. The company aids patients with congestive heart failure (CHF) and other chronic cardiopulmonary diseases by monitoring patient's health. It offers services such as remote health monitoring and teleconsultation services. It caters to old-age individuals. The company was founded in 2015 and is based in Israel, Tel Aviv.

A
Abbott

Abbott develops medical devices and solutions for cardiovascular conditions. It is based in Abbott Park, Illinois.

BrightInsight Logo
BrightInsight

BrightInsight provides a global platform for biopharma and MedTech regulated digital health solutions. The company helps accelerate time to market for apps, algorithms, medical devices, connected combination products, diagnostics, and Software as a Medical Device (SaMD). BrightInsight offers configurable software modules and a proven platform built under a Quality Management System to support global security, privacy, and regulatory requirements. When building digital health products on the BrightInsight Platform, compliance is future-proofed as intended use changes scale across geographies. The company was formerly known as Flex Digital Health and changed its name to BrightInsight. The company was founded in 2017 and is based in San Jose, California.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.